scholarly journals European clinical guidelines for Tourette syndrome and other tic disorders—version 2.0. Part IV: deep brain stimulation

Author(s):  
Natalia Szejko ◽  
Yulia Worbe ◽  
Andreas Hartmann ◽  
Veerle Visser-Vandewalle ◽  
Linda Ackermans ◽  
...  

AbstractIn 2011 the European Society for the Study of Tourette Syndrome (ESSTS) published its first European clinical guidelines for the treatment of Tourette Syndrome (TS) with part IV on deep brain stimulation (DBS). Here, we present a revised version of these guidelines with updated recommendations based on the current literature covering the last decade as well as a survey among ESSTS experts. Currently, data from the International Tourette DBS Registry and Database, two meta-analyses, and eight randomized controlled trials (RCTs) are available. Interpretation of outcomes is limited by small sample sizes and short follow-up periods. Compared to open uncontrolled case studies, RCTs report less favorable outcomes with conflicting results. This could be related to several different aspects including methodological issues, but also substantial placebo effects. These guidelines, therefore, not only present currently available data from open and controlled studies, but also include expert knowledge. Although the overall database has increased in size since 2011, definite conclusions regarding the efficacy and tolerability of DBS in TS are still open to debate. Therefore, we continue to consider DBS for TS as an experimental treatment that should be used only in carefully selected, severely affected and otherwise treatment-resistant patients.

2011 ◽  
Vol 20 (4) ◽  
pp. 209-217 ◽  
Author(s):  
Kirsten R. Müller-Vahl ◽  
◽  
Danielle C. Cath ◽  
Andrea E. Cavanna ◽  
Sandra Dehning ◽  
...  

2021 ◽  
Vol 11 (4) ◽  
pp. 461
Author(s):  
Francesca Morreale ◽  
Zinovia Kefalopoulou ◽  
Ludvic Zrinzo ◽  
Patricia Limousin ◽  
Eileen Joyce ◽  
...  

As part of the first randomized double-blind trial of deep brain stimulation (DBS) of the globus pallidus (GPi) in Tourette syndrome, we examined the effect of stimulation on response initiation and inhibition. A total of 14 patients with severe Tourette syndrome were recruited and tested on the stop signal task prior to and after GPi-DBS surgery and compared to eight age-matched healthy controls. Tics were significantly improved following GPi-DBS. The main measure of reactive inhibition, the stop signal reaction time did not change from before to after surgery and did not differ from that of healthy controls either before or after GPi-DBS surgery. This suggests that patients with Tourette syndrome have normal reactive inhibition which is not significantly altered by GPi-DBS.


2018 ◽  
Vol 75 (3) ◽  
pp. 353 ◽  
Author(s):  
Daniel Martinez-Ramirez ◽  
Joohi Jimenez-Shahed ◽  
James Frederick Leckman ◽  
Mauro Porta ◽  
Domenico Servello ◽  
...  

Neurosurgery ◽  
2006 ◽  
Vol 59 (2) ◽  
pp. 482
Author(s):  
Robert J. Maciunas ◽  
Brian Maddux ◽  
David E. Riley ◽  
Christina M. Whitney ◽  
Michael R. Schoenberg ◽  
...  

2012 ◽  
pp. 113-129
Author(s):  
L. Ackermans ◽  
I. Neuner ◽  
J. Kuhn ◽  
V. Visser-Vandewalle

2020 ◽  
Vol 46 (10) ◽  
pp. 668-673
Author(s):  
Rosemary T. Behmer Hansen ◽  
Arjun Dubey ◽  
Cynthia Smith ◽  
Patrick J. Henry ◽  
Antonios Mammis

Gilles de la Tourette syndrome (TS) is a childhood neuropsychiatric disorder characterised by the presence of motor and vocal tics. Patients with malignant TS experience severe disease sequelae; risking morbidity and mortality due to tics, self-harm, psychiatric comorbidities and suicide. By definition, those cases termed ‘malignant’ are refractory to all conventional psychiatric and pharmacological regimens. In these instances, deep brain stimulation (DBS) may be efficacious. Current 2015 guidelines recommend a 6-month period absent of suicidal ideation before DBS is offered to patients with TS. We therefore wondered whether it may be ethically justifiable to offer DBS to a minor with malignant TS. We begin with a discussion of non-maleficence and beneficence. New evidence suggests that suicide risk in young patients with TS has been underestimated. In turn, DBS may represent an invaluable opportunity for children with malignant TS to secure future safety, independence and fulfilment. Postponing treatment is associated with additional risks. Ultimately, we assert this unique risk-benefit calculus justifies offering DBS to paediatric patients with malignant TS. A multidisciplinary team of clinicians must determine whether DBS is in the best interest of their individual patients. We conclude with a suggestion for future TS-DBS guidelines regarding suicidal ideation. The importance of informed consent and assent is underscored.


2019 ◽  
Vol 62 ◽  
pp. 269-272 ◽  
Author(s):  
Massimo Marano ◽  
Simone Migliore ◽  
Ferdinando Squitieri ◽  
Angelo Insola ◽  
Eugenio Scarnati ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document